Mount Sinai researchers have discovered a dense network of cell-to-cell signaling that emerges in advanced fibrosis. More importantly, they have identified at least one antifibrotic drug target relating to this network, and a drug with which to target it—findings that may yield effective treatments for a disease that currently has no approved therapies.